Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Corvus Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CRVS
Nasdaq
8731
https://www.corvuspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Corvus Pharmaceuticals Inc
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
- Apr 17th, 2024 1:35 pm
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
- Apr 9th, 2024 8:01 pm
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
- Apr 1st, 2024 1:35 pm
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
- Mar 22nd, 2024 4:00 pm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
- Mar 21st, 2024 1:48 pm
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
- Mar 20th, 2024 10:32 am
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 19th, 2024 8:02 pm
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
- Mar 13th, 2024 8:02 pm
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
- Mar 9th, 2024 1:53 pm
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
- Feb 12th, 2024 1:30 pm
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
- Feb 8th, 2024 9:05 pm
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
- Feb 6th, 2024 9:05 pm
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
- Jan 23rd, 2024 10:00 pm
Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
- Jan 5th, 2024 10:12 am
What Makes Corvus (CRVS) a New Buy Stock
- Dec 11th, 2023 5:00 pm
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
- Dec 9th, 2023 5:00 pm
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
- Dec 7th, 2023 2:40 pm
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
- Nov 21st, 2023 2:40 pm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript
- Nov 8th, 2023 4:56 pm
Q3 2023 Corvus Pharmaceuticals Inc Earnings Call
- Nov 8th, 2023 1:43 pm
Scroll